Charles W. Drescher

Appointments and Affiliations
 
 
Pacific Gynecology Specialists
Swedish Medical Center
Gynecologic Oncology
 
Canary Foundation
Scientific Advisory Board
Member, Appointed: 2006
University of Washington
School of Medicine
Obstetrics and Gynecology
Clinical Professor, Appointed: 1998
Fred Hutchinson Cancer Research Center
Public Health Sciences
Molecular Diagnostics Program
Joint Member
 Professional Headshot of Charles W. Drescher

Mailing Address

Seattle, Washington 98109
United States

Degrees

M.D., University of Michigan, Medicine, 1982.

Research Interests

Dr. Drescher is a partner and gynecologic surgeon at Pacific Gynecology Specialists located on the Swedish Medical Center campus in Seattle, Washington. His primary academic appointments are with the University of Washington as a Clinical Professor in the Department of Obstetrics and Gynecology with a joint appointment to the Translational and Outcomes Research Group in the Molecular Diagnostics Program at the Fred Hutchinson Center as an Associate Member. Dr. Drescher earned his Medical Degree in Medicine at the University of Michigan in Ann Arbor, where he also completed a residency in Obstetrics and Gynecology and a fellowship in Gynecologic Oncology.

Dr. Drescher is a co-Principal Investigator of a Specialized Program of Research Excellence (SPORE) in Ovarian Cancer grant funded by the National Cancer Institute where he oversees the recruitment and enrollment of ovarian cancer patients into a surgical (tissue) donation program. Dr. Drescher has extensive experience in collecting and processing tissues and blood specimens from patients, which are banked in the SPORE's Specimen Repository for use in research studies. In addition, he co-leads a SPORE project focused on molecular targets for ovarian cancer prognosis and therapy. As an expert in gynecological oncology, Dr. Drescher is actively involved in many ovarian cancer research organizations including on the Cancer Prevention committee of the Gynecological Oncology Group (GOG) and the Executive Committees of the Puget Sound Oncology Consortium and Pacific Ovarian Cancer Research Consortium. He is the former Medical Director of the Marsha Rivkin Center for Ovarian Cancer Research.

Memberships

American Medical Association
Gynecologic Cancer Foundation
King County Medical Society
Seattle Gynecological Society
Society of Gynecologic Oncologists
Washington State Medical Association

Previous Positions

1996-2005, Medical Director, Marsha Rivkin Center for Ovarian Cancer Research
1991-1998, Clinical Assistant Professor, University of Washington, School of Medicine, Obstetrics and Gynecology
1987-1989, Instructor, University of Michigan, Gynecological Oncology, Medical Center
1986-1987, Guest Lecturer and Surgeon, Komfo Anokye Teaching Hospital

Funding

  • Canary Foundation: Development of a Blood-Based Assay for the Early Detection of Ovarian Cancer, 2005 to 2010.
  • National Institutes of Health (NIH): Modeling ovarian cancer screening for CEA, 2002 to 2006.
  • National Institutes of Health (NIH): Pacific Ovarian Cancer Research Consortium: SPORE in Ovarian Cancer, 1999 to 2009.

Recent Publications

2013
Drescher, CW, Shah C, Thorpe J, O'Briant K, Anderson GL, Berg CD, Urban ND, McIntosh MW.  2013.  Longitudinal Screening Algorithm That Incorporates Change Over Time in CA125 Levels Identifies Ovarian Cancer Earlier Than a Single-Threshold Rule.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(3):387-92. Abstract
Andersen, MR, Sweet E, Lowe KA, Standish LJ, Drescher CW, Goff BA.  2013.  Dangerous Combinations: Ingestible CAM Supplement Use During Chemotherapy in Patients with Ovarian Cancer.. Journal of alternative and complementary medicine (New York, N.Y.). Abstract
2012
Urban, ND, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, Paley P, Drescher CW.  2012.  Interpretation of Single and Serial Measures of HE4 and CA125 in Asymptomatic Women at High Risk for Ovarian Cancer.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 21(11):2087-94. Abstract
Andersen, MR, Sweet E, Lowe KA, Standish LJ, Drescher CW, Goff BA.  2012.  Involvement in decision-making about treatment and ovarian cancer survivor quality of life.. Gynecologic oncology. 124(3):465-470. Abstract
Drescher, CW, Hawley SH, Thorpe JD, Marticke S, McIntosh MW, Gambhir SS, Urban ND.  2012.  Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening.. Cancer prevention research (Philadelphia, Pa.). Abstract
Knouf, EC, Garg K, Arroyo JD, Correa Y, Sarkar D, Parkin RK, Wurz K, O'Briant KC, Godwin AK, Urban ND et al..  2012.  An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.. Nucleic acids research. 40(2):499-510. Abstract
2011
Salzman, J, Marinelli RJ, Wang PL, Green AE, Nielsen JS, Nelson BH, Drescher CW, Brown PO.  2011.  ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.. PLoS biology. 9(9):e1001156. Abstract
Skates, SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR et al..  2011.  Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.. Cancer prevention research (Philadelphia, Pa.). 4(9):1401-8. Abstract
Urban, ND, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, Scholler N, O'Briant KC, Anderson GL, Cramer DW, Berg CD et al..  2011.  Potential Role of HE4 in Multimodal Screening for Epithelial Ovarian Cancer.. Journal of the National Cancer Institute. 103(21):1630-4. Abstract
Lutz, AM, Willmann JK, Drescher CW, Ray P, Cochran FV, Urban ND, Gambhir SS.  2011.  Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology. 259(2):329-45. Abstract
Wang, H, Li Z-Y, Liu Y, Persson J, Beyer I, Möller T, Koyuncu D, Drescher MR, Strauss R, Zhang X-B et al..  2011.  Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.. Nature medicine. 17(1):96-104. Abstract
Strauss, R, Li Z-Y, Liu Y, Beyer I, Persson J, Sova P, Möller T, Pesonen S, Hemminki A, Hamerlik P et al..  2011.  Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity.. PloS one. 6(1):e16186. Abstract
2010
Andersen, MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P, Urban ND.  2010.  Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.. Gynecologic oncology. 116(3):378-83. Abstract
Anderson, GL, McIntosh MW, Wu LL, Barnett M, Goodman GE, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N et al..  2010.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.. Journal of the National Cancer Institute. 102(1):26-38. Abstract
Bendoraite, A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, Ventura AP, Godwin AK, Karlan BY, Drescher CW et al..  2010.  Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition.. Gynecologic oncology. 116(1):117-25. Abstract
Ventura, AP, Radhakrishnan S, Green A, Rajaram SK, Allen AN, O'Briant K, Schummer M, Karlan B, Urban ND, Tewari M et al..  2010.  Activation of the MEK-S6 pathway in high-grade ovarian cancers.. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. 18(6):499-508. Abstract
Houshdaran, S, Hawley S, Palmer C, Campan M, Olsen MN, Ventura AP, Knudsen BS, Drescher CW, Urban ND, Brown PO et al..  2010.  DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.. PloS one. 5(2):e9359. Abstract
Amon, LM, Law W, Fitzgibbon MP, Gross JA, O'Briant K, Peterson A, Drescher CW, Martin DB, McIntosh MW.  2010.  Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer.. PloS one. 5(6):e11137. Abstract
2009
Shah, CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD et al..  2009.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72. Abstract
Strauss, R, Sova P, Liu Y, Li ZY, Tuve S, Pritchard D, Brinkkoetter P, Möller T, Wildner O, Pesonen S et al..  2009.  Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.. Cancer research. 69(12):5115-25. Abstract
Sarkar, D, Parkin R, Wyman S, Bendoraite A, Sather C, Delrow JJ, Godwin AK, Drescher CW, Huber W, Gentleman R et al..  2009.  Quality assessment and data analysis for microRNA expression arrays.. Nucleic acids research. 37(2):e17. Abstract
Pan, S, Cheng L, White JT, Lu W, Utleg AG, Yan X, Urban ND, Drescher CW, Hood L, Lin B.  2009.  Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers.. Omics : a journal of integrative biology. 13(4):345-54. Abstract
Lowe, KA, Andersen MR, Urban ND, Paley P, Drescher CW, Goff BA.  2009.  The temporal stability of the Symptom Index among women at high-risk for ovarian cancer.. Gynecologic oncology. 114(2):225-30. Abstract
Schilder, RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW et al..  2009.  Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.. Gynecologic oncology. 113(1):21-7. Abstract
Wyman, SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban ND, Drescher CW, Knudsen BS, Tewari M.  2009.  Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries.. PloS one. 4(4):e5311. Abstract